<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 18:51:19 -0700</creation_date>
  <update_date>2013-05-27 11:34:41 -0600</update_date>
  <accession>HMDBP00698</accession>
  <secondary_accessions>
    <accession>5971</accession>
    <accession>HMDBP04887</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>5 alpha-SR2</synonym>
    <synonym>S5AR 2</synonym>
    <synonym>SR type 2</synonym>
    <synonym>Steroid 5-alpha-reductase 2</synonym>
    <synonym>Type II 5-alpha reductase</synonym>
  </synonyms>
  <gene_name>SRD5A2</gene_name>
  <general_function>Involved in 3-oxo-5-alpha-steroid 4-dehydrogenase activity</general_function>
  <specific_function>Converts testosterone (T) into 5-alpha-dihydrotestosterone (DHT) and progesterone or corticosterone into their corresponding 5-alpha-3-oxosteroids. It plays a central role in sexual differentiation and androgen physiology.
</specific_function>
  <pathways>
    <pathway>
      <name>Steroid hormone biosynthesis</name>
      <smpdb_id/>
      <kegg_map_id>map00140</kegg_map_id>
    </pathway>
    <pathway>
      <name>Prostate cancer</name>
      <smpdb_id/>
      <kegg_map_id>map05215</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB00053</accession>
      <name>Androstenedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00234</accession>
      <name>Testosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00899</accession>
      <name>Androstanedione</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02197</accession>
      <name>7a,12a-Dihydroxy-cholestene-3-one</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02833</accession>
      <name>Testosterone sulfate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02961</accession>
      <name>Dihydrotestosterone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB06886</accession>
      <name>7a,12a-Dihydroxy-5a-cholestan-3-one</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00784</accession>
      <name>Azelaic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15258</accession>
      <name>Dutasteride</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15347</accession>
      <name>Finasteride  e</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00217</accession>
      <name>NADP</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00221</accession>
      <name>NADPH</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity, acting on the ch-ch group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>oxidoreductase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid dehydrogenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>steroid dehydrogenase activity, acting on the ch-ch group of donors</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>oxidation reduction</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>primary metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>lipid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>steroid metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intracellular part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cytoplasm</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>endoplasmic reticulum membrane</description>
      <go_id>GO:0005789</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>integral to membrane</description>
      <go_id>GO:0016021</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>3-oxo-5-alpha-steroid 4-dehydrogenase activity</description>
      <go_id>GO:0003865</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>cholestenone 5-alpha-reductase activity</description>
      <go_id>GO:0047751</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>sterol 5-alpha reductase activity</description>
      <go_id>GO:0009917</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>androgen biosynthetic process</description>
      <go_id>GO:0006702</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell differentiation</description>
      <go_id>GO:0030154</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>cell-cell signaling</description>
      <go_id>GO:0007267</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>male gonad development</description>
      <go_id>GO:0008584</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Microsome membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
    <subcellular_location>Endoplasmic reticulum membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein (Potential)</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>2</chromosome_location>
    <locus>2p23</locus>
    <gene_sequence>&gt;765 bp
ATGCAGGTTCAGTGCCAGCAGAGCCCAGTGCTGGCAGGCAGCGCCACTTTGGTCGCCCTT
GGGGCACTGGCCTTGTACGTCGCGAAGCCCTCCGGCTACGGGAAGCACACGGAGAGCCTG
AAGCCGGCGGCTACCCGCCTGCCAGCCCGCGCCGCCTGGTTCCTGCAGGAGCTGCCTTCC
TTCGCGGTGCCCGCGGGGATCCTCGCCCGGCAGCCCCTCTCCCTCTTCGGGCCACCTGGG
ACGGTACTTCTGGGCCTCTTCTGCGTACATTACTTCCACAGGACATTTGTGTACTCACTG
CTCAATCGAGGGAGGCCTTATCCAGCTATACTCATTCTCAGAGGCACTGCCTTCTGCACT
GGAAATGGAGTCCTTCAAGGCTACTATCTGATTTACTGTGCTGAATACCCTGATGGGTGG
TACACAGACATACGGTTTAGCTTGGGTGTCTTCTTATTTATTTTGGGAATGGGAATAAAC
ATTCATAGTGACTATATATTGCGCCAGCTCAGGAAGCCTGGAGAAATCAGCTACAGGATT
CCACAAGGTGGCTTGTTTACGTATGTTTCTGGAGCCAATTTCCTCGGTGAGATCATTGAA
TGGATCGGCTATGCCCTGGCCACTTGGTCCCTCCCAGCACTTGCATTTGCATTTTTCTCA
CTTTGTTTCCTTGGGCTGCGAGCTTTTCACCACCATAGGTTCTACCTCAAGATGTTTGAG
GACTACCCCAAATCTCGGAAAGCCCTTATTCCATTCATCTTTTAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>254</residue_number>
    <molecular_weight>28407.035</molecular_weight>
    <theoretical_pi>9.395</theoretical_pi>
    <pfams>
      <pfam>
        <name>Steroid_dh</name>
        <pfam_id>PF02544</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;3-oxo-5-alpha-steroid 4-dehydrogenase 2
MQVQCQQSPVLAGSATLVALGALALYVAKPSGYGKHTESLKPAATRLPARAAWFLQELPS
FAVPAGILARQPLSLFGPPGTVLLGLFCVHYFHRTFVYSLLNRGRPYPAILILRGTAFCT
GNGVLQGYYLIYCAEYPDGWYTDIRFSLGVFLFILGMGINIHSDYILRQLRKPGEISYRI
PQGGLFTYVSGANFLGEIIEWIGYALATWSLPALAFAFFSLCFLGLRAFHHHRFYLKMFE
DYPKSRKALIPFIF</protein_sequence>
  </protein_properties>
  <genbank_protein_id>338469</genbank_protein_id>
  <uniprot_id>P31213</uniprot_id>
  <uniprot_name>S5A2_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>M74047</genbank_gene_id>
  <genecard_id>SRD5A2</genecard_id>
  <geneatlas_id>SRD5A2</geneatlas_id>
  <hgnc_id>HGNC:11285</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Andersson S, Berman DM, Jenkins EP, Russell DW: Deletion of steroid 5 alpha-reductase 2 gene in male pseudohermaphroditism. Nature. 1991 Nov 14;354(6349):159-61.</reference_text>
      <pubmed_id>1944596</pubmed_id>
    </reference>
    <reference>
      <reference_text>Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N: Structure of human type II 5 alpha-reductase gene.  Endocrinology. 1992 Sep;131(3):1571-3.</reference_text>
      <pubmed_id>1505484</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Thigpen AE, Davis DL, Milatovich A, Mendonca BB, Imperato-McGinley J, Griffin JE, Francke U, Wilson JD, Russell DW: Molecular genetics of steroid 5 alpha-reductase 2 deficiency.  J Clin Invest. 1992 Sep;90(3):799-809.</reference_text>
      <pubmed_id>1522235</pubmed_id>
    </reference>
    <reference>
      <reference_text>Boudon C, Lobaccaro JM, Lumbroso S, Ogur G, Ocal G, Belon C, Sultan C: A new deletion of the 5 alpha-reductase type 2 gene in a Turkish family with 5 alpha-reductase deficiency. Clin Endocrinol (Oxf). 1995 Aug;43(2):183-8.</reference_text>
      <pubmed_id>7554313</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cai LQ, Zhu YS, Katz MD, Herrera C, Baez J, DeFillo-Ricart M, Shackleton CH, Imperato-McGinley J: 5 alpha-reductase-2 gene mutations in the Dominican Republic.  J Clin Endocrinol Metab. 1996 May;81(5):1730-5.</reference_text>
      <pubmed_id>8626825</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hochberg Z, Chayen R, Reiss N, Falik Z, Makler A, Munichor M, Farkas A, Goldfarb H, Ohana N, Hiort O: Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 alpha-reductase 2 deficiency. J Clin Endocrinol Metab. 1996 Aug;81(8):2821-7.</reference_text>
      <pubmed_id>8768837</pubmed_id>
    </reference>
    <reference>
      <reference_text>Anwar R, Gilbey SG, New JP, Markham AF: Male pseudohermaphroditism resulting from a novel mutation in the human steroid 5 alpha-reductase type 2 gene (SRD5A2). Mol Pathol. 1997 Feb;50(1):51-2.</reference_text>
      <pubmed_id>9208814</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nordenskjold A, Magnus O, Aagenaes O, Knudtzon J: Homozygous mutation (A228T) in the 5alpha-reductase type 2 gene in a boy with 5alpha-reductase deficiency: genotype-phenotype correlations. Am J Med Genet. 1998 Nov 16;80(3):269-72.</reference_text>
      <pubmed_id>9843052</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nordenskjold A, Ivarsson SA: Molecular characterization of 5 alpha-reductase type 2 deficiency and fertility in a Swedish family. J Clin Endocrinol Metab. 1998 Sep;83(9):3236-8.</reference_text>
      <pubmed_id>9745434</pubmed_id>
    </reference>
    <reference>
      <reference_text>Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK: Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999 Sep 18;354(9183):975-8.</reference_text>
      <pubmed_id>10501358</pubmed_id>
    </reference>
    <reference>
      <reference_text>Vilchis F, Mendez JP, Canto P, Lieberman E, Chavez B: Identification of missense mutations in the SRD5A2 gene from patients with steroid 5alpha-reductase 2 deficiency. Clin Endocrinol (Oxf). 2000 Mar;52(3):383-7.</reference_text>
      <pubmed_id>10718838</pubmed_id>
    </reference>
    <reference>
      <reference_text>Chavez B, Valdez E, Vilchis F: Uniparental disomy in steroid 5alpha-reductase 2 deficiency.  J Clin Endocrinol Metab. 2000 Sep;85(9):3147-50.</reference_text>
      <pubmed_id>10999800</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pearce CL, Makridakis NM, Ross RK, Pike MC, Kolonel LN, Henderson BE, Reichardt JK: Steroid 5-alpha reductase type II V89L substitution is not associated with risk of prostate cancer in a multiethnic population study. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):417-8.</reference_text>
      <pubmed_id>11927504</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sasaki G, Ogata T, Ishii T, Kosaki K, Sato S, Homma K, Takahashi T, Hasegawa T, Matsuo N: Micropenis and the 5alpha-reductase-2 (SRD5A2) gene: mutation and V89L polymorphism analysis in 81 Japanese patients. J Clin Endocrinol Metab. 2003 Jul;88(7):3431-6.</reference_text>
      <pubmed_id>12843198</pubmed_id>
    </reference>
    <reference>
      <reference_text>Loukola A, Chadha M, Penn SG, Rank D, Conti DV, Thompson D, Cicek M, Love B, Bivolarevic V, Yang Q, Jiang Y, Hanzel DK, Dains K, Paris PL, Casey G, Witte JS: Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2. Eur J Hum Genet. 2004 Apr;12(4):321-32.</reference_text>
      <pubmed_id>14560315</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fernandez-Cancio M, Rodo J, Andaluz P, Martinez de Osaba MJ, Rodriguez-Hierro F, Esteban C, Carrascosa A, Audi L: Clinical, biochemical and morphologic diagnostic markers in an infant male pseudohermaphrodite patient with compound heterozygous mutations (G115D/R246W) in SRD5A2 gene. Horm Res. 2004;62(5):259-64. Epub 2004 Nov 2.</reference_text>
      <pubmed_id>15528927</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nicoletti A, Baldazzi L, Balsamo A, Barp L, Pirazzoli P, Gennari M, Radetti G, Cacciari E, Cicognani A: SRD5A2 gene analysis in an Italian population of under-masculinized 46,XY subjects. Clin Endocrinol (Oxf). 2005 Oct;63(4):375-80.</reference_text>
      <pubmed_id>16181229</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hackel C, Oliveira LE, Ferraz LF, Tonini MM, Silva DN, Toralles MB, Stuchi-Perez EG, Guerra-Junior G: New mutations, hotspots, and founder effects in Brazilian patients with steroid 5alpha-reductase deficiency type 2. J Mol Med. 2005 Jul;83(7):569-76. Epub 2005 Mar 16.</reference_text>
      <pubmed_id>15770495</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bahceci M, Ersay AR, Tuzcu A, Hiort O, Richter-Unruh A, Gokalp D: A novel missense mutation of 5-alpha reductase type 2 gene (SRD5A2) leads to severe male pseudohermaphroditism in a Turkish family. Urology. 2005 Aug;66(2):407-10.</reference_text>
      <pubmed_id>16098368</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Azelaic acid</name>
        <accession>HMDB00784</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azelaic acid</name>
        <accession>HMDB00784</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Azelaic acid</name>
        <accession>HMDB00784</accession>
      </metabolite>
      <reference>
        <reference_text>Stamatiadis D, Bulteau-Portois MC, Mowszowicz I: Inhibition of 5 alpha-reductase activity in human skin by zinc and azelaic acid.  Br J Dermatol. 1988 Nov;119(5):627-32.</reference_text>
        <pubmed_id>3207614</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Rathnayake D, Sinclair R: Male androgenetic alopecia.  Expert Opin Pharmacother. 2010 Jun;11(8):1295-304.</reference_text>
        <pubmed_id>20426708</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Aggarwal S, Thareja S, Verma A, Bhardwaj TR, Kumar M: An overview on 5alpha-reductase inhibitors.  Steroids. 2010 Feb;75(2):109-53. Epub 2009 Oct 30.</reference_text>
        <pubmed_id>19879888</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12.</reference_text>
        <pubmed_id>19707263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.</reference_text>
        <pubmed_id>19543428</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Keam SJ, Scott LJ: Dutasteride: a review of its use in the management of prostate disorders.  Drugs. 2008;68(4):463-85.</reference_text>
        <pubmed_id>18318566</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9.</reference_text>
        <pubmed_id>16818707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Rittmaster RS, Fleshner NE, Thompson IM: Pharmacological approaches to reducing the risk of prostate cancer.  Eur Urol. 2009 May;55(5):1064-73. Epub 2009 Feb 5.</reference_text>
        <pubmed_id>19200641</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dutasteride</name>
        <accession>HMDB15258</accession>
      </metabolite>
      <reference>
        <reference_text>Shah SK, Trump DL, Sartor O, Tan W, Wilding GE, Mohler JL: Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy. J Urol. 2009 Feb;181(2):621-6. Epub 2008 Dec 16.</reference_text>
        <pubmed_id>19091347</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM: Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003 Aug;74(2):393-406. Epub 2003 May 28.</reference_text>
        <pubmed_id>12773767</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT: Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006 Jul 1;12(13):4072-9.</reference_text>
        <pubmed_id>16818707</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Ha SJ, Kim JS, Myung JW, Lee HJ, Kim JW: Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. J Dermatol Sci. 2003 Apr;31(2):135-41.</reference_text>
        <pubmed_id>12670724</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Suzuki R, Satoh H, Ohtani H, Hori S, Sawada Y: Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug Metab Pharmacokinet. 2010;25(2):208-13.</reference_text>
        <pubmed_id>20460827</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Smith AB, Carson CC: Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009 Jun;5(3):535-45. Epub 2009 Jul 12.</reference_text>
        <pubmed_id>19707263</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Goldenberg L, So A, Fleshner N, Rendon R, Drachenberg D, Elhilali M: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 2009 Jun;3(3 Suppl 2):S109-14.</reference_text>
        <pubmed_id>19543428</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Finasteride  e</name>
        <accession>HMDB15347</accession>
      </metabolite>
      <reference>
        <reference_text>Joseph MA, Jayaseelan E, Ganapathi B, Stephen J: Hidradenitis suppurativa treated with finasteride.  J Dermatolog Treat. 2005 Apr;16(2):75-8.</reference_text>
        <pubmed_id>16019620</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
